Letter to the Editor regarding the article “SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis”
- 4 May 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Heart Failure Reviews
- Vol. 27 (3), 981-982
- https://doi.org/10.1007/s10741-021-10111-y
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysisHeart Failure Reviews, 2021
- Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseThe New England Journal of Medicine, 2021
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureThe New England Journal of Medicine, 2021
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionCirculation, 2018
- Random-effects model for meta-analysis of clinical trials: An updateContemporary Clinical Trials, 2007